Ardelyx (FRA:41X) Current Accrued Expense : €24.7 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Current Accrued Expense?

Ardelyx's Current Accrued Expense for the quarter that ended in Dec. 2024 was €24.7 Mil.

Ardelyx's quarterly Current Accrued Expense increased from Jun. 2024 (€24.8 Mil) to Sep. 2024 (€30.0 Mil) but then declined from Sep. 2024 (€30.0 Mil) to Dec. 2024 (€24.7 Mil).

Ardelyx's annual Current Accrued Expense increased from Dec. 2022 (€9.3 Mil) to Dec. 2023 (€9.3 Mil) and increased from Dec. 2023 (€9.3 Mil) to Dec. 2024 (€24.7 Mil).

Ardelyx Current Accrued Expense Historical Data

The historical data trend for Ardelyx's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Current Accrued Expense Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

4.11

5.48

9.29

9.32

24.72

Ardelyx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Accrued Expense	Get a 7-Day Free Trial															9.32	20.23	24.82	30.00	24.72

Ardelyx Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Ardelyx Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Ardelyx's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ARDX:USA 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines